Citadel Advisors
DFTX

Citadel Advisors’s Definium Therapeutics DFTX Stock Holding History

Citadel Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.32M Sell
70,100
-103,400
-60% -$1.75M ﹤0.01% 7020
2025
Q4 		$2.32M Buy
173,500
+9,000
+5% +$111K ﹤0.01% 5634
2025
Q3 		$1.94M Sell
164,500
-40,800
-20% -$380K ﹤0.01% 6128
2025
Q2 		$1.33M Sell
205,300
-31,100
-13% -$205K ﹤0.01% 6488
2025
Q1 		$1.38M Buy
236,400
+79,700
+51% +$571K ﹤0.01% 6247
2024
Q4 		$1.09M Buy
156,700
+33,100
+27% +$228K ﹤0.01% 6828
2024
Q3 		$703K Buy
123,600
+30,300
+32% +$211K ﹤0.01% 7535
2024
Q2 		$673K Sell
93,300
-80,300
-46% -$702K ﹤0.01% 7433
2024
Q1 		$1.63M Buy
173,600
+72,802
+72% +$415K ﹤0.01% 5913
2023
Q4 		$369K Sell
100,798
-6,257
-6% -$18.8K ﹤0.01% 8731
2023
Q3 		$335K Buy
107,055
+68,158
+175% +$280K ﹤0.01% 8938
2023
Q2 		$139K Sell
38,897
-88,748
-70% -$306K ﹤0.01% 10443
2023
Q1 		$405K Buy
127,645
+39,600
+45% +$132K ﹤0.01% 8746
2022
Q4 		$194K Sell
88,045
-81,774
-48% -$227K ﹤0.01% 10194
2022
Q3 		$594K Buy
169,819
+141,466
+499% +$1.36M ﹤0.01% 8086
2022
Q2 		$272K Buy
28,353
+5,166
+22% +$65.4K ﹤0.01% 10023
2022
Q1 		$386K Buy
23,187
+5,467
+31% +$94.8K ﹤0.01% 10002
2021
Q4 		$367K Sell
17,720
-7,900
-31% -$252K ﹤0.01% 10454
2021
Q3 		$895K Sell
25,620
-4,960
-16% -$214K ﹤0.01% 8438
2021
Q2 		$1.58M Buy
+30,580
New +$1.61M ﹤0.01% 7189

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors's DFTX Position: Q1 2026 in Review

Citadel Advisors increased its Definium Therapeutics (DFTX) stake by 535% in Q1 2026, buying an estimated $19.1M and bringing the position to 1,333,442 shares worth $25.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2051.

Citadel Advisors first reported a position in DFTX in Q2 2021 and has held it in 19 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Citadel Advisors held 1,333,442 shares of Definium Therapeutics worth $25.2M as of Q1 2026.
  • Citadel Advisors bought 1,123,498 Definium Therapeutics shares in Q1 2026, an estimated $19.1M.
  • Definium Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2051 holding.
  • Citadel Advisors first reported a position in Definium Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.